WallStreetZenWallStreetZen

NASDAQ: RGEN
Repligen Corp Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for RGEN

Based on 9 analysts offering 12 month price targets for Repligen Corp

Min Forecast
$135.00-18.56%
Avg Forecast
$168.78+1.82%
Max Forecast
$204.00+23.07%

Should I buy or sell RGEN stock?

Based on 9 analysts offering ratings for Repligen Corp.

Strong Buy
Strong Buy
4 analysts 44.44%
Buy
3 analysts 33.33%
Hold
2 analysts 22.22%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although RGEN's forecast from analysts indicates a "Strong Buy", our proven Zen Rating quant model rates RGEN as a "Hold". Stocks with a Zen Rating of Hold have had an average return of +7.53% per year. Learn More

Be the first to know when Wall Street analysts revise their RGEN stock forecasts and price targets.

RGEN stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-10-29
lockedlocked$00.00+00.00%2025-10-29
lockedlocked$00.00+00.00%2025-10-07
lockedlocked$00.00+00.00%2025-10-01
lockedlocked$00.00+00.00%2025-09-12
HC Wainwright & Co.
Top 1%
100
BuyReiterates$180.00+8.59%2025-09-03
RBC Capital
Bottom 2%
2
BuyMaintains$204.00+23.07%2025-07-30
Wells Fargo
Top 23%
78
Strong BuyMaintains$175.00+5.57%2025-07-30
Stephens & Co.
Top 48%
53
Strong BuyAssumes$160.00-3.47%2025-07-22

1 of 1

Forecast return on equity

Is RGEN forecast to generate an efficient return?

Company
9.74%
Industry
22.82%
Market
228.88%
RGEN's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is RGEN forecast to generate an efficient return on assets?

Company
6.94%
Industry
17.09%
RGEN is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

RGEN earnings per share forecast

What is RGEN's earnings per share in the next 3 years based on estimates from 25 analysts?

Avg 1 year Forecast
$1.70+8,403%
Avg 2 year Forecast
$2.12+10,482%
Avg 3 year Forecast
$2.73+13,527.5%
RGEN's earnings are forecast to... subscribe to Premium to read more.
Forecast High Earnings Growth Forecast

RGEN revenue forecast

What is RGEN's revenue in the next 3 years based on estimates from 25 analysts?

Avg 1 year Forecast
$747.6M+5.61%
Avg 2 year Forecast
$841.6M+18.89%
Avg 3 year Forecast
$967.9M+36.73%
RGEN's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

RGEN earnings growth forecast

How is RGEN forecast to perform vs Medical Instruments & Supplies companies and vs the US market?

Company
412.01%
Industry
27.3%
Market
42.81%
RGEN's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Industry Forecast
RGEN's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Market Forecast
RGEN's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Savings Rate Forecast

RGEN revenue growth forecast

How is RGEN forecast to perform vs Medical Instruments & Supplies companies and vs the US market?

Company
10.73%
Industry
7.9%
Market
25.69%
RGEN's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
RGEN's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

RGEN vs Medical Stocks

TickerPricePrice TargetUp/downsideConsensus
RGEN$165.76$168.78+1.82%Strong Buy
BAX$18.48$24.38+31.90%Hold
ATR$122.02$167.50+37.27%Strong Buy
STVN$22.92$24.00+4.71%Hold
BLCO$16.81$17.50+4.10%Buy
View Top Medical Stocks

Repligen Stock Forecast FAQ

Is Repligen Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 9 Wall Street analysts covering (NASDAQ: RGEN) stock is to Strong Buy RGEN stock.

Out of 9 analysts, 4 (44.44%) are recommending RGEN as a Strong Buy, 3 (33.33%) are recommending RGEN as a Buy, 2 (22.22%) are recommending RGEN as a Hold, 0 (0%) are recommending RGEN as a Sell, and 0 (0%) are recommending RGEN as a Strong Sell.

If you're new to stock investing, here's how to buy Repligen stock.

What is RGEN's earnings growth forecast for 2025-2027?

(NASDAQ: RGEN) Repligen's forecast annual earnings growth rate of 412.01% is forecast to beat the US Medical Instruments & Supplies industry's average forecast earnings growth rate of 27.3%, and it is also forecast to beat the US market's average forecast earnings growth rate of 42.81%.

Repligen's earnings in 2025 is $1,738,000.On average, 25 Wall Street analysts forecast RGEN's earnings for 2025 to be $95,728,048, with the lowest RGEN earnings forecast at $91,022,141, and the highest RGEN earnings forecast at $100,478,987. On average, 24 Wall Street analysts forecast RGEN's earnings for 2026 to be $119,133,741, with the lowest RGEN earnings forecast at $97,090,284, and the highest RGEN earnings forecast at $134,349,131.

In 2027, RGEN is forecast to generate $153,420,436 in earnings, with the lowest earnings forecast at $118,604,608 and the highest earnings forecast at $177,732,411.

What is RGEN's revenue growth forecast for 2025-2027?

(NASDAQ: RGEN) Repligen's forecast annual revenue growth rate of 10.73% is forecast to beat the US Medical Instruments & Supplies industry's average forecast revenue growth rate of 7.9%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 25.69%.

Repligen's revenue in 2025 is $707,890,000.On average, 25 Wall Street analysts forecast RGEN's revenue for 2025 to be $42,084,652,675, with the lowest RGEN revenue forecast at $40,231,561,218, and the highest RGEN revenue forecast at $43,418,743,426. On average, 24 Wall Street analysts forecast RGEN's revenue for 2026 to be $47,375,983,081, with the lowest RGEN revenue forecast at $43,808,838,317, and the highest RGEN revenue forecast at $50,071,184,143.

In 2027, RGEN is forecast to generate $54,482,127,235 in revenue, with the lowest revenue forecast at $50,696,574,364 and the highest revenue forecast at $58,148,343,717.

What is RGEN's forecast return on assets (ROA) for 2025-2028?

(NASDAQ: RGEN) forecast ROA is 6.94%, which is lower than the forecast US Medical Instruments & Supplies industry average of 17.09%.

What is RGEN's Price Target?

According to 9 Wall Street analysts that have issued a 1 year RGEN price target, the average RGEN price target is $168.78, with the highest RGEN stock price forecast at $204.00 and the lowest RGEN stock price forecast at $135.00.

On average, Wall Street analysts predict that Repligen's share price could reach $168.78 by Oct 29, 2026. The average Repligen stock price prediction forecasts a potential upside of 1.82% from the current RGEN share price of $165.76.

What is RGEN's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: RGEN) Repligen's current Earnings Per Share (EPS) is $0.02. On average, analysts forecast that RGEN's EPS will be $1.70 for 2025, with the lowest EPS forecast at $1.62, and the highest EPS forecast at $1.79. On average, analysts forecast that RGEN's EPS will be $2.12 for 2026, with the lowest EPS forecast at $1.72, and the highest EPS forecast at $2.39. In 2027, RGEN's EPS is forecast to hit $2.73 (min: $2.11, max: $3.16).

What is RGEN's forecast return on equity (ROE) for 2025-2028?

(NASDAQ: RGEN) forecast ROE is 9.74%, which is considered weak.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.